Skip to main content

Table 3 TTC-related event rate > 34% according to proportion of toxicity

From: Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma

Expected overall adverse event (Proportion) Adverse event rate (Null proportion) Lower critical value Power
5% 34% 1 88.2%
10% 34% 1 65.9%
15% 34% 1 44.3%
20% 34% 1 27.5%